Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV
Por um escritor misterioso
Descrição
Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in
Immunogenicity of a DNA vaccine candidate for COVID-19
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19), Cellular & Molecular Biology Letters
Vaccines, Free Full-Text
Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults
Vaccines, Free Full-Text
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India - eClinicalMedicine
Current clinical status of new COVID-19 vaccines and immunotherapy
Innovative Vaccines to Fight COVID-19, Other Viruses - IEEE Pulse
Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model
SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies - ScienceDirect
EX-99.1
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations - Bulent Kantarcioglu, Omer Iqbal, Joseph Lewis, Charles A. Carter, Meharvan Singh, Fabio Lievano
de
por adulto (o preço varia de acordo com o tamanho do grupo)
